38.62
price up icon0.73%   0.28
after-market Handel nachbörslich: 38.60 -0.02 -0.05%
loading
Schlusskurs vom Vortag:
$38.34
Offen:
$38.91
24-Stunden-Volumen:
2.68M
Relative Volume:
0.93
Marktkapitalisierung:
$7.33B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-16.02
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
+12.76%
1M Leistung:
+4.55%
6M Leistung:
+34.14%
1J Leistung:
+42.40%
1-Tages-Spanne:
Value
$38.27
$39.67
1-Wochen-Bereich:
Value
$34.13
$39.67
52-Wochen-Spanne:
Value
$21.62
$39.67

Bridgebio Pharma Inc Stock (BBIO) Company Profile

Name
Firmenname
Bridgebio Pharma Inc
Name
Telefon
(650) 391-9740
Name
Adresse
3160 PORTER DR., PALO ALTO, CA
Name
Mitarbeiter
730
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BBIO's Discussions on Twitter

Vergleichen Sie BBIO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
BBIO
Bridgebio Pharma Inc
38.62 6.34B 217.77M -438.86M -456.33M -2.41
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.232 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.34 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 65.36B 14.09B 4.50B 2.96B 39.28

Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-31 Eingeleitet Redburn Atlantic Buy
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-10-03 Eingeleitet Oppenheimer Perform
2024-09-04 Eingeleitet Piper Sandler Overweight
2024-03-21 Fortgesetzt Raymond James Outperform
2024-01-31 Eingeleitet BMO Capital Markets Market Perform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-11-07 Eingeleitet Citigroup Buy
2023-10-24 Eingeleitet Cantor Fitzgerald Overweight
2023-07-18 Herabstufung Jefferies Buy → Hold
2023-04-19 Eingeleitet Evercore ISI Outperform
2023-02-06 Eingeleitet Cowen Outperform
2021-12-27 Bestätigt Mizuho Buy
2021-12-27 Bestätigt SVB Leerink Outperform
2021-09-10 Hochstufung BofA Securities Neutral → Buy
2021-05-21 Eingeleitet UBS Buy
2021-03-22 Bestätigt Goldman Buy
2021-02-22 Fortgesetzt JP Morgan Overweight
2021-02-09 Fortgesetzt Goldman Buy
2021-01-11 Bestätigt H.C. Wainwright Buy
2020-12-10 Bestätigt H.C. Wainwright Buy
2020-06-25 Eingeleitet BofA/Merrill Neutral
2020-05-19 Eingeleitet BTIG Research Buy
2020-04-13 Eingeleitet H.C. Wainwright Buy
2020-02-19 Eingeleitet Mizuho Buy
2019-07-26 Eingeleitet Raymond James Outperform
2019-07-22 Eingeleitet BMO Capital Markets Outperform
2019-07-22 Eingeleitet Goldman Buy
2019-07-22 Eingeleitet JP Morgan Overweight
2019-07-22 Eingeleitet Jefferies Buy
2019-07-22 Eingeleitet Piper Jaffray Overweight
2019-07-22 Eingeleitet SVB Leerink Outperform
Alle ansehen

Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten

pulisher
10:18 AM

BridgeBio Pharma stock hits 52-week high at $39.58 - Investing.com

10:18 AM
pulisher
08:35 AM

Piper Sandler maintains overweight rating on BridgeBio Pharma stock - Investing.com

08:35 AM
pulisher
Jun 05, 2025

BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

BridgeBio price target raised to $42 from $37 at BMO Capital - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

BridgeBio (BBIO) Target Price Raised by BMO Capital | BBIO Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Exploring High Growth Tech Stocks In The US Market - simplywall.st

Jun 04, 2025
pulisher
Jun 04, 2025

BridgeBio: New Data Bolsters The Bull Case (NASDAQ:BBIO) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 02, 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

BridgeBio Management Reveals Latest Genetic Disease Strategy at Goldman Sachs Healthcare Conference 2025 - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

BridgeBio Pharma (NASDAQ:BBIO) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Jun 01, 2025
pulisher
May 28, 2025

Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 28, 2025
pulisher
May 27, 2025

Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st

May 27, 2025
pulisher
May 26, 2025

BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria

May 26, 2025
pulisher
May 26, 2025

Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com

May 26, 2025
pulisher
May 24, 2025

Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 24, 2025
pulisher
May 21, 2025

The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey

May 21, 2025
pulisher
May 21, 2025

Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com

May 21, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan

May 20, 2025
pulisher
May 19, 2025

BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

BridgeBio Pharma Reports Phase 3 Data Linking TTR Increase to Improved Survival With Acoramidis - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

BridgeBio’s acoramidis shows promise in ATTR-CM study - Investing.com

May 19, 2025
pulisher
May 19, 2025

BridgeBio Pharma Reports Positive Phase 3 Results for Acoramidis, Highlighting Improved Survival Rates in ATTR-CM Patients - Nasdaq

May 19, 2025
pulisher
May 19, 2025

Breakthrough ATTR-CM Study: Higher TTR Levels from Acoramidis Directly Predict 31% Better Survival Rates - Stock Titan

May 19, 2025
pulisher
May 15, 2025

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN

May 15, 2025
pulisher
May 14, 2025

Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade - MSN

May 14, 2025
pulisher
May 14, 2025

Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Fibroblast Growth Factors (FGFs) Market reached US$ 303.75 - openPR.com

May 14, 2025
pulisher
May 14, 2025

BridgeBio Expands Team with 101,974 Shares in RSU Grants to 36 New Biotech Talents - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Massive Sell-Offs Just Hit These 10 Stocks Today - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

BridgeBio (BBIO) Begins Dosing in ACT-EARLY Trial with Acoramidis | BBIO Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

BridgeBio launches landmark ATTR prevention study - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - The Manila Times

May 13, 2025
pulisher
May 13, 2025

BridgeBio launches landmark ATTR prevention study By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 12, 2025

BridgeBio to Present Clinical Outcomes, Quality of Life Measures - GuruFocus

May 12, 2025
pulisher
May 12, 2025

BridgeBio Pharma to Present Key Findings on Acoramidis at Heart Failure Association Congress 2025 - Nasdaq

May 12, 2025
pulisher
May 12, 2025

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - The Manila Times

May 12, 2025
pulisher
May 11, 2025

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

May 11, 2025
pulisher
May 10, 2025

(BBIO) Trading Report - news.stocktradersdaily.com

May 10, 2025
pulisher
May 10, 2025

Raymond James Financial Inc. Invests $456,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World

May 10, 2025
pulisher
May 07, 2025

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 - The Manila Times

May 07, 2025
pulisher
May 06, 2025

Recursion cuts nearly half of its pipeline - statnews.com

May 06, 2025
pulisher
May 05, 2025

Achondroplasia Market: Epidemiology, Therapies, Companies, - openPR.com

May 05, 2025
pulisher
May 05, 2025

Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $53, Maintains Outperform Rating - marketscreener.com

May 05, 2025

Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Bridgebio Pharma Inc-Aktie (BBIO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Kumar Neil
Chief Executive Officer
May 19 '25
Sale
33.33
26,156
871,764
217,404
$1.15
price up icon 0.00%
$585.93
price up icon 0.92%
$300.83
price down icon 2.33%
$38.11
price up icon 4.30%
$4.73
price down icon 1.69%
$493.22
price up icon 2.10%
Kapitalisierung:     |  Volumen (24h):